Urogen Pharma (NASDAQ:URGN) Receives $33.29 Consensus PT from Brokerages

Shares of Urogen Pharma (NASDAQ:URGN) have been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $33.2857.

A number of research analysts recently commented on URGN shares. Oppenheimer reaffirmed an “outperform” rating on shares of Urogen Pharma in a research report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, January 21st. Finally, D. Boral Capital reissued a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research note on Monday, March 2nd.

Urogen Pharma Stock Down 4.1%

URGN opened at $17.17 on Thursday. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $30.00. The firm has a market cap of $835.84 million, a price-to-earnings ratio of -5.37 and a beta of 1.34. The company’s 50-day moving average price is $19.88 and its 200 day moving average price is $20.76.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, March 2nd. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million during the quarter, compared to analyst estimates of $39.92 million. Research analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,479 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $147,261.51. Following the transaction, the general counsel owned 51,326 shares in the company, valued at $1,010,608.94. The trade was a 12.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mark Schoenberg sold 7,373 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total value of $145,174.37. Following the sale, the insider directly owned 144,985 shares of the company’s stock, valued at $2,854,754.65. This trade represents a 4.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 4.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

Large investors have recently made changes to their positions in the company. Invesco Ltd. raised its position in Urogen Pharma by 21.1% during the fourth quarter. Invesco Ltd. now owns 27,066 shares of the company’s stock valued at $634,000 after acquiring an additional 4,711 shares in the last quarter. Susquehanna Portfolio Strategies LLC acquired a new position in shares of Urogen Pharma during the 4th quarter worth $641,000. Superstring Capital Management LP increased its stake in shares of Urogen Pharma by 717.1% during the 4th quarter. Superstring Capital Management LP now owns 718,354 shares of the company’s stock worth $16,824,000 after purchasing an additional 630,442 shares during the last quarter. Orbimed Advisors LLC raised its holdings in shares of Urogen Pharma by 27.1% during the 4th quarter. Orbimed Advisors LLC now owns 875,487 shares of the company’s stock valued at $20,504,000 after purchasing an additional 186,487 shares in the last quarter. Finally, Opaleye Management Inc. bought a new position in shares of Urogen Pharma during the 4th quarter valued at $6,286,000. Institutional investors own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.